Related Experiment Video
Updated: Jul 13, 2025

Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Management strategies for severe Pseudomonas aeruginosa infections
Hermann Do Rego1, Jean-François Timsit1,2,3
1AP-HP, Bichat Hospital, Medical and infectious diseases intensive care unit.
Purpose Of Review:
This review focuses on the management of severe Pseudomonas aeruginosa infections in critically ill patients.
Recent Findings:
Pseudomonas aeruginosa is the most common pathogen in intensive care; the main related infections are nosocomial pneumonias, then bloodstream infections. Antimicrobial resistance is common; despite new antibiotics, it is associated with increased mortality, and can lead to a therapeutic deadlock.
Summary:
Carbapenem resistance in difficult-to-treat P. aeruginosa (DTR-PA) strains is primarily mediated by loss or reduction of the OprD porin, overexpression of the cephalosporinase AmpC, and/or overexpression of efflux pumps. However, the role of carbapenemases, particularly metallo-β-lactamases, has become more important. Ceftolozane-tazobactam, ceftazidime-avibactam and imipenem-relebactam are useful against DTR phenotypes (noncarbapenemase producers). Other new agents, such as aztreonam-ceftazidime-avibactam or cefiderocol, or colistin, might be effective for carbapenemase producers. Regarding nonantibiotic agents, only phages might be considered, pending further clinical trials. Combination therapy does not reduce mortality, but may be necessary for empirical treatment. Short-term treatment of severe P. aeruginosa infections should be preferred when it is expected that the clinical situation resolves rapidly.
Insights
Managing severe Pseudomonas aeruginosa infections in critically ill patients requires careful antibiotic selection due to rising antimicrobial resistance. New agents offer hope against difficult-to-treat strains, but clinical trials are ongoing.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Antimicrobial Resistance
Background:
- Pseudomonas aeruginosa is a leading cause of intensive care unit infections, including pneumonia and bloodstream infections.
- Antimicrobial resistance in P. aeruginosa contributes to increased mortality and treatment challenges.
- Difficult-to-treat P. aeruginosa (DTR-PA) strains exhibit complex resistance mechanisms.
Conclusions:
- Effective management of severe P. aeruginosa infections hinges on understanding resistance patterns and utilizing appropriate novel agents.
- Combination therapy may be necessary for empirical treatment, though it doesn't reduce mortality.
- Short-term treatment is preferred when rapid clinical improvement is anticipated.
More Related Videos
07:25Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Gene Regulation in Microbial Communities: Quorum Sensing
Hand hygiene
Hand washing...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...